Humacyte (NASDAQ:HUMA) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Humacyte (NASDAQ:HUMA) in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $7.00 price target on the stock.

Several other brokerages also recently issued reports on HUMA. Piper Sandler reiterated a neutral rating and set a $4.00 price target on shares of Humacyte in a research report on Tuesday, March 26th. Benchmark restated a buy rating and set a $15.00 target price on shares of Humacyte in a research report on Tuesday.

Humacyte Stock Down 4.8 %

Shares of NASDAQ HUMA opened at $5.11 on Tuesday. The firm’s 50-day simple moving average is $5.95 and its 200 day simple moving average is $4.22. The company has a market cap of $608.50 million, a price-to-earnings ratio of -5.11 and a beta of 1.52. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.61. Humacyte has a 12-month low of $1.96 and a 12-month high of $9.97.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). On average, research analysts expect that Humacyte will post -0.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Humacyte

In other Humacyte news, COO Heather Ledbetter Prichard sold 188,886 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $8.14, for a total transaction of $1,537,532.04. Following the transaction, the chief operating officer now directly owns 2,625 shares in the company, valued at approximately $21,367.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, COO Heather Ledbetter Prichard sold 188,886 shares of the company’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $8.14, for a total value of $1,537,532.04. Following the completion of the sale, the chief operating officer now directly owns 2,625 shares of the company’s stock, valued at approximately $21,367.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Brady W. Dougan sold 271,518 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total value of $1,982,081.40. Following the completion of the sale, the director now directly owns 4,559,140 shares of the company’s stock, valued at $33,281,722. The disclosure for this sale can be found here. In the last three months, insiders have acquired 54,412 shares of company stock worth $369,107 and have sold 1,628,820 shares worth $12,464,121. Corporate insiders own 23.10% of the company’s stock.

Institutional Trading of Humacyte

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in Humacyte during the 1st quarter worth approximately $197,000. Anson Funds Management LP bought a new stake in Humacyte during the 1st quarter worth approximately $156,000. Vanguard Group Inc. increased its stake in Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after purchasing an additional 896,415 shares in the last quarter. Capstone Investment Advisors LLC bought a new stake in Humacyte during the 1st quarter worth approximately $972,000. Finally, Private Advisor Group LLC increased its stake in Humacyte by 232.7% during the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock worth $988,000 after purchasing an additional 222,144 shares in the last quarter. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.